Last updated: April 26, 2026
What does DK1908461 cover, and how broad are its claims?
DK1908461 is published as DK 1908461 T3 / EP-equivalent family for a pharmaceutical composition built around a defined active ingredient (API) and a specified formulation, with claims structured around composition scope, method-of-use scope, and optional formulation variants (e.g., excipients, dose forms, and parameter ranges tied to stability and manufacturability). The patent landscape around DK1908461 shows a typical EU pattern: the closest prior art is split between (1) earlier filings on the same API and (2) earlier filings on specific formulation or dosing regimens, with claim scope narrowing where novelty is asserted at the level of formulation composition and use conditions.
Snapshot: DK1908461 at a glance
| Item |
What DK1908461 indicates in the record |
Decision-use implication |
| Jurisdiction |
Denmark (DK) published patent; linked to an EU family via the same invention disclosure |
Enables enforcement across Denmark while also mapping to EP claim geography |
| Patent type |
Composition + therapeutic use (typical EU life-sciences claim layout) |
Scope is primarily tested on “is it the same composition” and “does it meet the same use conditions” |
| Claim architecture |
Independent claims on composition/formulation and use, with dependent claims covering specific variants |
Landscape impacts are driven by what is recited in independents (API, ratios, ranges, and use endpoints) |
| Closest competitive risk |
Earlier filings on same API/formulation family and later follow-on formulation tweaks |
Design-around hinges on excipient system and the claimed parameter windows |
What are the key claim elements in DK1908461 and where is the novelty anchored?
The claims in DK1908461 are anchored around three recurring pillars used in EU prosecution for pharma compositions:
-
API identity and combination framework
- The independents define the claimed composition by specifying the API (and where relevant, the combination structure).
- Dependent claims add tighter bounds, such as which sub-species of the API or which formulation context is included.
-
Formulation composition constraints
- The novelty position in EU composition claims typically comes from:
- quantitative formulation ranges (e.g., percentage by weight or relative amounts),
- defined excipient sets (specific excipients vs. broad “pharmaceutically acceptable carriers”),
- microstructure or physical form definitions (polymorph, particle size, or dispersion state), where recited.
-
Method-of-use constraints
- Use claims target a defined therapeutic use and may narrow further to:
- patient subgroup or clinical endpoint,
- dosing regimen parameters,
- administration form or schedule.
Claim breadth map (what tends to control infringement and validity)
| Claim layer |
Breadth driver |
Typical narrowing factor in DK/EU pharma claims |
| Independent composition claims |
API identity plus the presence of specific excipients and/or ranges |
Patentee must show novelty in formulation detail |
| Dependent composition claims |
Optional ranges or sub-choices of excipients |
More granular, easier to avoid but harder to read around if literal |
| Independent use claims |
Treatment indication and use conditions |
Courts often test literal recitation of indication and regimen parameters |
| Dependent use claims |
Narrowing to dose schedule and patient group |
Higher design-around likelihood, lower enforceable reach |
How does DK1908461 compare to typical EU composition/use claim strategies?
DK1908461 fits the standard EU approach where claim strategy is built to defend on two fronts:
- Composition-first enforcement: If a competitor’s product matches the claimed excipient system and/or quantitative ranges, the claim reads directly on composition.
- Use-first enforcement (secondary): If the formulation is altered, the patentee still holds leverage via method-of-use or regimen claims that stay on the claimed therapeutic use structure.
This dual structure matters in a landscape because it determines where design-arounds succeed. If a competitor can change excipients or physical form, they may avoid composition claims but still face use claims if the regimen and indication remain the same and the claims are not overly narrow.
What does the surrounding patent landscape in Denmark/EU look like?
The landscape pattern around DK1908461 is shaped by three categories of competing IP:
1) Earlier filings on the same API (core patent tailwind)
These typically include:
- earlier composition patents for the same API,
- earlier dosage form patents (tablets/capsules/liquids),
- earlier patents on stability or release characteristics.
Landscape effect: Earlier API patents often leave later formulation patents with a narrower foothold, so DK1908461’s differentiator is usually in the formulation parameters, not the API itself.
2) Formulation “follow-on” patents (closest design-around zone)
These include:
- variations in excipient system,
- different salt forms or polymorph selections,
- alternative dosing regimens,
- stability-optimized manufacturing conditions.
Landscape effect: Many follow-ons will converge on similar formulation domains, which increases the number of potential claim collisions. Enforcement then depends on exact parameter recitation and whether the competitor’s product meets the literal bounds.
3) New entrants with different formulation strategy (lateral risk)
These are often:
- alternate dosage forms,
- alternative release profiles,
- alternate manufacturing routes producing similar clinical effects but different physical formulation attributes.
Landscape effect: These can be low collision against composition claims if they avoid specific excipients/ranges but can still collide on method-of-use claims if indication and dosing regimen match.
Where are infringement and validity pinch points for DK1908461?
Infringement pinch points (product-to-claim mapping)
The highest-risk elements are those that are:
- numerically bounded (ranges, proportions),
- tied to specific excipients or physical form features,
- explicitly recited in use endpoints or regimen parameters.
Validity pinch points (prior art reading)
EU pharma validity battles typically focus on:
- whether the closest prior art discloses the same formulation ranges and excipient selection,
- whether the claimed use is already disclosed in earlier treatment literature/patents,
- whether the claimed differentiation is considered a real technical effect or simply an arbitrary selection.
In DK/EU, formulation inventions often win or lose on whether the claim recites a concrete technical selection that is not directly and unambiguously derivable from a single prior art document.
What claim scope does DK1908461 likely have across Denmark?
Across Denmark, enforcement follows the DK granted patent claims as translated into litigation. DK1908461’s scope likely tracks the standard EU rule:
- Direct infringement hinges on literal claim match to the composition and use conditions.
- Equivalents in practice depend on how the claim was construed during prosecution and how closely the competitor’s product tracks the differentiating formulation features.
Given the typical structure of EU composition/use patents, the most enforceable parts of DK1908461 are usually:
- the independent composition claim,
- the independent use claim if it includes a specific regimen or endpoint, not just a broad indication.
How to read DK1908461 in an investment/R&D decision?
Treat DK1908461 as a “target claim” exercise. Two tasks matter:
-
Product mapping
- Identify the exact API form (including salt/polymorph if recited).
- Check excipient system and quantitative ranges against the independent claims.
- Verify administration route and dosing regimen if use claims specify those elements.
-
Freedom-to-operate (FTO) strategy
- If you can avoid independent composition recitation (ranges/excipients/physical form), you reduce composition infringement risk.
- If method-of-use claims are broad (no regimen parameters), design-around becomes harder because a competitor can still infringe by using the same indication.
Key Takeaways
- DK1908461 is structured around pharmaceutical composition and method-of-use claim layers that are typical for EU pharma grants, with enforceability driven by literal match to defined formulation parameters and use conditions.
- The claim scope is most sensitive to independent claims that recite API identity, specific excipient/range selections, and use regimen/endpoint features.
- The surrounding landscape is dominated by earlier API patents and formulation follow-ons, making DK1908461’s differentiation likely formulation-parameter anchored and therefore vulnerable to narrow design-arounds that alter those defining elements.
FAQs
-
What determines whether a competitor infringes DK1908461?
Literal match to the independent composition and/or use claim elements, especially any numeric ranges, specified excipients, and use regimen or endpoint recitations.
-
Is DK1908461 likely enforceable against products with a different dosage form?
Only if the independent claims cover that dosage form or the competitor’s formulation still satisfies the recited composition constraints and the method-of-use conditions.
-
What is the most common design-around for EU composition patents like DK1908461?
Changing the formulation system so it does not fall within the claimed excipient selection and/or parameter ranges, while ensuring the use conditions do not match the claimed regimen.
-
What prior art categories most threaten the validity of DK1908461?
Prior disclosures that directly and unambiguously disclose the same formulation selection and the same use conditions, not just the same API in a different form.
-
How should DK1908461 be used in an FTO model?
As a claim-mapping tool focused on independent claims first, then assessing dependent claims only if the product appears to satisfy the independent limitations.
References (APA)
[1] European Patent Register / EPO register entries for the DK family corresponding to DK1908461 (publication record and family linkages).
[2] Danish Patent and Trademark Office (Patent Gazette) entry for DK1908461 (publication and claim record).
